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Abstract
Purpose: To develop a novel biological dosimetric margin (BDM) and to create a
biological conversion factor (BCF) that compensates for the difference between
physical dosimetric margin (PDM) and BDM, which provides a novel scheme of a
direct estimation of the BDM from the physical dose (PD) distribution.
Methods: The offset to isocenter was applied in 1‐mm steps along left‐right (LR),
anterior‐posterior (AP), and cranio‐caudal (CC) directions for 10 treatment plans of
lung stereotactic body radiation therapy (SBRT) with a prescribed dose of 48 Gy.
These plans were recalculated to biological equivalent dose (BED) by the linear‐
quadratic model for the dose per fraction (DPF) of d = 3–20 Gy/fr and
α=β ¼ 3 10. BDM and PDM were defined so that the region that satisfied that
the dose covering 95% (or 98%) of the clinical target volume was greater than or
equal to the 90% of the prescribed PD and BED, respectively. An empirical formula
of the BCF was created as a function of the DPF.
Results: There was no significant difference between LR and AP directions for nei-
ther the PDM nor BDM. On the other hand, BDM and PDM in the CC direction
were significantly larger than in the other directions. BCFs of D95% and D98% were
derived for the transverse (LR and AP) and longitudinal (CC) directions.
Conclusions: A novel scheme to directly estimate the BDM using the BCF was
developed. This technique is expected to enable the BED‐based SBRT treatment
planning using PD‐based treatment planning systems.
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1 | INTRODUCTION
In modern radiation therapy, dose‐volume histogram (DVH) and iso-
dose distribution are commonly used for treatment evaluation. Dose‐
volume constraints indicate organ volumes that should not receive
doses exceeding certain limits derived from retrospective studies.
Clinical and radiobiological studies have shown that two treatments
delivering the same total dose through different fractionation
schemes produce different biological results.1,2 Fowler showed that
the biological effective dose (BED) modeling is a valuable tool for
understanding tumor and normal tissue response across different
treatment modalities and fractionation schemes.3 Based on the idea
of BED, it has been shown that the relative biological effectiveness
depends on the dose per fraction (DPF) and the number of fractions.
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Particularly, stereotactic body radiation therapy (SBRT) requires the
calculation of BED, as it uses hypo‐fractionations and results in the
delivery of a high BED. In these studies, linear quadratic (LQ) model
was used. The LQ model is the most commonly used tool to model
the effect of fractionation in conventionally fractionated radiother-
apy and to predict tumor response to altered fractionation regimens.
Technical advances in radiation therapy, including three‐dimen-
sional conformal radiotherapy (3D‐CRT) and, more recently, inten-
sity‐modulated radiotherapy (IMRT) has simultaneously enabled dose
escalation and enhanced normal tissue sparing. ICRU 50 and 62
Reports were widely used as an international reference for the pre-
scribing, recording, and reporting of photon beam radiotherapy.4,5
However, the ICRU 83 Report was released in 2010 specifically
addressing IMRT and introducing some different concepts and plan
evaluation parameters such as volumetric planning target volume
(PTV) prescribing.6 For SBRT, clinical trials RTOG 02367 and 08138
used the volume prescription method.9 The dose that covered 95 %
of the PTV (D95%) was conformal in the treatment plan using the
volume prescription.10,11 The variation of the peripheral dose of PTV
is expected to be significantly reduced using this prescribing method.
To accommodate inter‐ and intra‐fractional patient setup uncer-
tainties and organ motions, the International Commission on Radia-
tion Units and Measurements, Inc. (ICRU) recommends expanding
the clinical target volume (CTV) by a margin to obtain PTV.12 In past
studies, the van Herk formula was generally used for calculating the
PTV margin from the systematic and random errors of the CTV. This
formula ensures that the minimum dose of the CTV is equal to or
greater than 95% of the prescribed dose for 90% of the popula-
tion.13 However, the treated volume (TV) is usually larger than the
PTV, resulting in a mismatch between the theory and application of
the van Herk formula.
Gordon and Siebers introduced a new concept, termed the dosi-
metric margin (DM), to explain the sensitivity of a group of prostate
IMRT treatment plans to patient setup errors.14 The TV was defined
as a volume covered by the minimum dose of the PTV. The DM,
which is a margin achieved between the CTV and TV for a given
plan, is a generalization of the conformity index.15 Importantly, the
sensitivity of the CTV dose to setup errors is a function of the DM.
Thus, the target coverage by the isodose surface of interest (e.g.,
D95%) should be evaluated using the DM, rather than the CTV‐to‐
PTV margin, in the presence of setup errors. However, the DM does
not consider the difference in dose distribution by setup uncertainty.
Moreover, the DM proposed by Gordon was defined using only the
physical dose (PD) calculation. In practice, there are many fractiona-
tion schemes for SBRT (e.g., 48 Gy/4 fr, 60 Gy/3 fr etc.). Therefore,
it is considered to be essential to take the biological effect such as
DPF into account to provide appropriate DM for each fractionation
scheme.
In this study, we introduced a DM involving the effects of the
dose perturbation due to the setup uncertainty to take into account
the setup errors in the clinical practice. The DM was defined as the
isocenter shift that the CTV is satisfied with a certain dose level by
setup uncertainty. The DM with physical dose distribution is
defined as the physical dosimetric margin (PDM). Moreover, we
proposed a novel quantity, named biological dosimetric margin
(BDM), which was a margin distribution considering the biological
effect of the DM. The biological effect was introduced by calculat-
ing the BED using the LQ model16 as an example biological model.
The differences between the relative dose distribution of the PD
and BED were calculated. The relative BED distribution was ana-
lyzed for the dose per fraction (DPF) from 3 to 20 Gy/fr. The α=β
of the tumor and normal tissue were used different values. The α=β
of the PTV includes the tumor was 3, 5, and 10 Gy, and that of
the normal tissue was 3 Gy.17–20 To provide appropriate DM for
each fractionation scheme in BED‐based treatment planning, a bio-
logical conversion factor (BCF) between BDM and PDM was intro-
duced by considering the DPF and α=β to create a simple model of
the BDM.
2 | MATERIALS AND METHODS
Ten cases of patients with lung cancer, who underwent SBRT at (in-
stitution name), were analyzed. The characteristics of the patients
and their tumors are presented in Table 1. The use of clinical materi-
als in this study was approved by the Institutional Review Board of
(institution name).
Figure 1 shows the process of the evaluating the BDM and
PDM. The physical dose distribution was created in RayStation (Ray-
Search, Stockholm, Sweden). The physical dose distribution was con-
verted to the BED distribution using the LQ model (Step 1). The
dose distribution with the setup uncertainty was created using the
“perturbed dose calculation” in RayStation, which the isocenter is
shifted from −20 to 20 mm along left‐right (LR), anterior‐posterior
(AP), cranio‐caudal (CC) directions (Step 2). These calculations were
performed for both physical and biological dose distributions. TV
were then derived from the perturbed dose distributions. The aniso-
tropic PDM and BDM were calculated from CTV and TV (Step 3).
The BCF model was developed to provide a conversion from the
PDM to the BDM (Step 4).
The details of the treatment planning and BED are described in
Sections 2.1 and 2.2, respectively. The perturbed dose calculation,
TV, and DM are described in detail in Section 2.3. The evaluations
TAB L E 1 Patient characteristics.
Age (years) Median 78
Range 58–90
Gender Male 7 (70%)
Female 3 (30%)
Tumor location Right lobe 6 (60%)
Left lobe 4 (40%)
Tumor diameter (mm) 0–10 3 (30%)
10–20 4 (40%)
20–30 3 (30%)
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of the BDM, PDM, and BCF are given in Section 2.4. In addition, the
dose gradient in the physical dose and BED was investigated in Sec-
tion 2.5.
2.A | Treatment planning
All patients were immobilized using a Vac‐Lok cushion (CIVCO,
Kalona, IA, USA). Breath‐holding was coordinated in the expiratory
phase using Abches (APEX Medical, Tokyo, Japan) — a device that
allowed patients to control their chest and abdominal respiratory
motion.21 The tumor position reproducibility during several expira-
tory breath‐hold intervals was verified to be within 5 mm using X‐
ray fluoroscopy. Computed tomography (CT) scans were performed
during the expiratory breath‐holding using a CT scanner (LightSpeed
RT16, GE Healthcare, Little Chalfont, UK). Both the slice thickness
and the slice interval were 1.25 mm. The diameter of the tumor was
equal to or smaller than 3 cm in the clinical cases investigated in this
study.
The CTV margin was 0 mm around the GTV. The reproducibil-
ity of the tumor position at respiratory breath‐hold was suppressed
within 5 mm using the breath‐hold technique with Abches.22 Sys-
tematic error of the tumor position is corrected with the daily
Cone‐beam CT. A PTV margin of 5 mm in left‐right (LR), anterior‐
posterior (AP), and cranio‐caudal (CC) directions around the CTV
including the respiratory motion reproducibility and the setup error
was usually added. The isocenter (IC) was defined at the centroid
of the GTV. Eight beams with coplanar and noncoplanar angles
were used for every patient. If possible, the beam directions were
set such that the beams did not cross the critical OARs, such as
the contralateral lung and spinal cord. The dose constraint for nor-
mal lung was the combined percentage of lung volume receiving a
dose of 20 Gy or higher (V20 Gy) is below 20%. The dose con-
straint for the spinal cord was the maximum dose is below 25 Gy.
A TrueBeam linear accelerator (Varian Medical Systems, Palo Alto,
USA) was used for producing 6‐MV flattening filter free beams.
The treatment plans with a prescribed dose of 48 Gy for D95% of
the PTV was created using the superposition/convolution algorithm
on RayStation.
2.B | Biological equivalent dose
The BED was calculated using the LQ model as an example model
to create the BED. The LQ model fits the cell‐surviving fraction
through a second‐order polynomial on the DPF,
Cell  surviving fraction ¼ exp αd βd2 ; (1)
where d is the DPF. The BED is then defined by




where n is the number of treatment fractions. The ratio α=β
describes the repair capacity of the cells, and thus the sensitivity to
the fractionation. In the calculation of relative BED, DPF, and α=β
were mainly affected with a constant DPF. The BED distribution
was calculated from the physical dose distribution using Eq. (2). In
this study, α=β was varied along 3, 5, and 10.23 The DPF was in the
range 3–20 Gy, referring to the past clinical trials shown in Table 2.
2.C | Treated volume and dosimetric margin
Figure 2 shows illustrations of the TV and DM in this study in com-
parison with the ones by Gordon and Siebers.14 The TV by Gordon
F I G . 1 . The process of the evaluating the biological dosimetric margin (BDM) and physical dosimetric margin (PDM).
TAB L E 2 The past clinical trials for lung SBRT that used different






Shien et al.24 33–50 3–5 50–60%
margin
Onimaru et al.25 48–60 6–7.5 Point dose
Uematsu et al.26 50–60 10 80% margin
Nagata et al.27 48 12 Point dose
Taremi et al.28 48 12 80% margin
Wulf et al.29 45–56.2 15–15.4 80% margin
Olsen et al.30 50, 54 10, 18 80% margin
Timmerman
et al.31
24–60 8–20 80% margin
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where DROIX denotes the dose to the region of interest (ROI) and X =
min., max., 95%, etc. The DM by Gordon and Siebers14 (DMG) was
then defined as a volume achieved between the CTV and TV. These
definitions are given based on a treatment plan with no blurring of
the isocenter.
In this study, the TV was defined so that the dose perturbation
effects due to the setup error were taken into account [Fig. 2(b)].
The setup error was generated by shifting the isocenter (IC) along
LR, AP, and CC directions from −20 to +20 mm with a 1‐mm step
(δL, δR, δA, δP, δCr, and δCa, respectively). The dose distributions were
calculated with the shifted isocenter. The TV is defined as a volume
that satisfied
TV ¼ VDCTV
95% or 98%ð Þ ≥ 0:9  DRx ; (4)
where DRx denotes the prescribed dose. The DROIX denotes the dose
to the region of interest (ROI) and X = 95%, 98% in the physical and
biological dose distributions by shifting the isocenter. Next, the max-
imum shift toward the left, right, anterior, posterior, cranio, and cau-
dal directions (ΔL, ΔR, ΔA, ΔP, ΔCr, and ΔCa, respectively) that passed
criteria of Eq. (5) were determined.
DCTV95% or 98%ð Þ ≥ 0:9  DRx: (5)
Here, the scale of the DM in this study that is the distance and
the DMG that is the volume are different. The DM along each direc-
tion was calculated by
DMx ¼ ΔL þ ΔRð Þ=2; (6)
DMy ¼ ΔA þ ΔPð Þ=2; and (7)
DMz ¼ ΔCr þ ΔCað Þ=2; : (8))
Thus, the DM in this study, DMx; DMy; DMzð Þ, is anisotropic
which includes the dose perturbation effects induced by the isocen-
ter shift. The DM was calculated for both the physical and biological
dose distributions.
2.D | Evaluations of BDM and PDM
The DM in physical dose distribution is defined as PDM and the DM in
BED is defined as BDM. The physical dose distribution and BED are
defined as the BDM and PDM. The mean value and standard error of
the mean (SEM) of the BDM and PDM of the 10 cases were evaluated
for DPF from 3 to 20 Gy/fr. The data were compared using Student's
t‐test. The first test was performed to compare the BDM and PDM
along the LR, AP and CC directions. The LQ model was applied with
α=β fixed to 10 Gy, as it is universally accepted for conventional frac-
tionation.32 The second test was performed to compare the BDM and
PDM with α=β = 3, 5, and 10 Gy. All statistical analyses were per-
formed using SPSS Statistics (IBM, Armonk, NY, USA). The statistical
significance was defined for the P < 0.05. Also, the correlation factor
(r2) of the tumor volume and PDM or BDM is analyzed. Then, The BCF




The correlation of the BCF and α=β is evaluated. After confirming
there is no significant difference for the BCF due to the α=β, the
BCF is fitted using the following function of d= α=βð Þ.




where A, B, and C are the fitting parameters determined by a least
squares method. These parameters were determined for the
F I G . 2 . Illustrations of the treated
volume (TV) and dosimetric margin (DM)
by (a) Gordon and Siebers14 and (b) our
study. See text for details.
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measurement data of D95% and D98% in the LR, AP, and CC
directions.
2.E | Evaluations of dose gradient in physical dose
and BED
The dose gradient (DG) was calculated with dose profile in the
physical dose and BED, as shown in Fig. 3. The dose distribution
was normalized to the prescribed dose as 100%. The distance
between the dh and dl that were the position at a certain relative
dose of higher dose (Dh) (%) and lower dose (Dl) (%). The DG can be
defined by




The average DG in the LR, AP, and CC directions were defined
as DGLR, DGAP, and DGCC, respectively.
DGLR ¼ DGR þDGLð Þ=2; (12)
DGAP ¼ DGA þDGPð Þ=2; and (13)
DGCC ¼ DGCr þDGCað Þ=2: (14)
Then, the DG in physical dose distribution (DGPD) and the DG in
BED (DGBED) were derived by
DGPD ¼ DGPDLR þ DGPDAP þ DGPDCC
 .
3; (15))




3.A | Dose gradient in physical dose and BED
Figure 4 shows the average DGPD and DGBED for the all directions
in 10 patients. The average DGPD of 10 patients was 1.7%/mm and
DGBED at the DPF of 3–20 Gy with α=β = 10 Gy of 10 patients
were 2.4%–2.9%/mm. The DGPD is significantly smaller than the
DGBED at the DPF of 3–20 Gy with α=β = 10 Gy.
3.B | Comparison of the physical and biological
dosimetric margins
Figures 5 and 6 show the BDM and PDM (α=β = 10 Gy) for the
DCTV95% and D
CTV
98% of CTV in the LR, AP, and CC directions for all
patients. The DPF ranged from 3 to 20 Gy. The difference between
the BDM and PDM of D95% was 0.5–1.3, 0.6–1.4, and 0.6–1.3 mm
in the LR, AP, and CC directions, respectively (Fig. 5). The difference
between the BDM and PDM of D98% was 0.5–1.2, 0.6–1.3, and 0.5–
F I G . 3 . The scheme of the lung tumor
and isodose line (left) and the dose
gradient (DG) in the dose profile (right).
The dl and dh are the distance from the
isocenter at Dl and Dh that are higher and
lower dose. The Dl and Dh are the 85%
and 95% of the prescribed dose.
F I G . 4 . The DGPD and DGBED with the
d= α=βð Þ. The dose per fraction (DPF)
ranged from 3 to 20 Gy with α=β = 10 Gy.
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1.2 mm for the LR, AP, and CC directions, respectively (Fig. 6). The
PDM was larger than the BDM, and the BDM was smaller for large
DPF in all directions. There was no significant difference in LR and
AP directions for neither the BDM nor PDM (P > 0.05). On the
other hand, both the BDM and PDM in the CC direction were signif-
icantly larger than the ones in the other directions (P < 0.05) in both
D95% and D98%.
3.C | Correlation of the tumor volume and the DM
Figure 7 shows the correlation of the tumor volume and PDM for
the DCTV95% of CTV in the LR, AP, and CC directions. The r
2 for the
tumor volume and PDM in LR, AP, and CC directions were 0.18,
0.07, and 0.64, respectively. Figure 8 shows the correlation of the
tumor volume and BDM (α=β = 10 Gy) for the DCTV95% of CTV with
DPR = 3 and 20 Gy in the LR, AP, and CC directions. The r2 for the
tumor volume and BDM with DPR = 3 Gy in LR, AP, and CC direc-
tions were 0.18, 0.03, and 0.59, respectively. The r2 for the tumor
volume and BDM with DPR = 20 Gy in LR, AP, and CC directions
were 0.20, 0.04, and 0.42, respectively.
3.D | Biological conversion factor
Figures 9 and 10 show the BCF for the DCTV95% and D
CTV
98% of CTV with
α=β = 3, 5, 10 Gy in the LR, AP, and CC directions. The BCF is smaller
with higher DPF and lower α=β. Figures 11 and 12 show the BCF for
the DCTV95% and D
CTV
98% of CTV with d= α=βð Þ in the LR, AP, and CC direc-
tions. The differences in the BCF due to α=β for the DCTV95% and D
CTV
98% of
CTV were not significantly. The data of the transverse direction (LR
and AP directions) were combined for the fitting since there was no
significant difference between the LR and AP directions. The fitting
results of the BCF are shown in Fig. 13. Figure 13(a) shows the mea-
surement data and the fitted curve of D95% in the transverse and CC
directions, respectively. Figure 13(b) show the measurement data and
the fitted curve of D98% in the transverse and CC directions, respec-
tively. The resulting parameters of the BCF are shown in Fig. 13.
4 | DISCUSSION
In a past study, van Herk reported that the PTV should be a geomet-
rical concept, and van Herk's margin was defined to select the
F I G . 5 . Measured biological dosimetric
margin (BDM) and physical dosimetric
margin (PDM; the margin corresponding to
the 90% coverage of the planned D95% of
clinical target volume [CTV] with biological
equivalent dose [BED] and physical dose
[PD] distribution) at the dose per fraction
(DPF) of 3–20 Gy with α=β = 10 Gy in (a)
LR, (b) AP, and (c) CC directions. AP,
anterior‐posterior; CC, cranio‐caudal; LR,
left‐right.
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appropriate beam sizes and arrangements, taking into consideration
the net effect of all the possible geometrical variations and inaccura-
cies to obtain a clinically acceptable and specified probability that
the prescribed dose is absorbed in the CTV.13 Gordon and Siebers
reported the use of the DM, which extended the concept of the
CTV‐to‐PTV margin.14 The DM by Gordon was defined as the
F I G . 6 . Measured biological dosimetric
margin (BDM) and physical dosimetric
margin (PDM) (the margin corresponding
to the 90% coverage of the planned D98%
of clinical target volume [CTV] with
biological equivalent dose [BED] and
physical dose [PD] distribution) at the dose
per fraction (DPF) of 3–20 Gy with
α=β = 10 Gy in (a) LR, (b) AP, and (c) CC
directions. AP, anterior‐posterior; CC,
cranio‐caudal; LR, left‐right.
F I G . 7 . The correlation of the tumor
volume and the physical dosimetric margin
(PDM) of the DCTV95% in (a) LR, (b) AP, (c) CC
directions. AP, anterior‐posterior; CC,
cranio‐caudal; LR, left‐right.
F I G . 8 . The correlation of the tumor
volume and the biological dosimetric
margin (BDM) of the DCTV95% with 10 Gy of
α=β in (a) LR, (b) AP, (c) CC directions. AP,
anterior‐posterior; CC, cranio‐caudal; LR,
left‐right.
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distance between the CTV and the region of the minimum PTV
dose. These concepts were introduced as an isotropic margin from
the CTV. On the other hand, the DM along the LR, AP and CC direc-
tions were independently defined in this study. The DM in the CC
direction was found to be larger than the other directions. This
result is an indication that the anisotropic nature of the DM intro-
duced in this study would be useful to provide an appropriate 3D
margin. The importance of the anisotropic margin is supported by
the results in Caivano et al.33 They reported that the CT with a thin
slice thickness could be suggested for small targets, such as those
treatable with the stereotactic radiotherapy, to achieve a better
tumor definition and dose coverage. The resolution of the dose cov-
erage of the target depends on the slice thickness in the CC direc-
tion. Thus, it would be beneficial to use the anisotropic DM to
create a reasonable 3D dose distribution with a minimum 3D margin.
Moreover, the correlation between the tumor volume and DM
(BDM and PDM) was evaluated. This correlation is weaker, which
indicates that the size of the target volume does not affect the
BDM and PDM in this study.
There are various patient positioning uncertainties such as respi-
ratory motion, the breath‐hold reproducibility, contouring, and resid-
ual set up errors for SBRT treatment.34,35 The manifestation of the
isocenter shift depends on the type of the immobilization, respira-
tory gating or breath‐holding, and irradiation techniques. While the
dose perturbation due to the setup error was mimicked by systemat-
ically moving the isocenter along the LR, AP, and CC directions in
this study, the BCF can be adjusted to give a dedicated model for
specific technique by replacing the 3D isocenter shift by the actual
distribution of the setup error.
The essential outcome of this study is the novel scheme to
involve the biological effects into the DM. The BED suggested in
past studies3,24–31 has been an important subject to consider the
difference in the prescribed dose. Specifically, the SBRT is per-
formed with various fractionations and prescribed doses at differ-
ent institutions. The difference in the DPF affects the biological
damage. While the treatment plan review is usually performed on
the PD in the clinical practice, it is essential to consider the differ-
ence in the DPF. The BDM was smaller than PDM in all directions
F I G . 9 . The biological conversion factor (BCF) of D95% at the dose
per fraction (DPF) of 3–20 Gy with α=β = 3, 5, 10 Gy in the (a) LR,
(b) AP, and (c) CC directions. Closed squares, closed triangles, and
cross symbols show the BCFs for α=β = 3, 5, 10 Gy, respectively.
AP, anterior‐posterior; CC, cranio‐caudal; LR, left‐right.
F I G . 10 . The biological conversion factor (BCF) of D98% at the
dose per fraction (DPF) of 3–20 Gy with α=β = 3, 5, 10 Gy in the (a)
LR, (b) AP, and (c) CC directions. Closed squares, closed triangles,
and cross symbols show the BCFs for α=β = 3, 5, 10 Gy,
respectively. AP, anterior‐posterior; CC, cranio‐caudal; LR, left‐right.
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F I G . 11 . The biological conversion factor (BCF) of D98% with the
d= α=βð Þ in the (a) LR, (b) AP, and (c) CC directions. Closed squares,
closed triangles, and cross symbols show the BCFs for α=β = 3, 5,
10 Gy, respectively. AP, anterior‐posterior; CC, cranio‐caudal; LR,
left‐right.
F I G . 12 . The biological conversion factor (BCF) of D98% with the
d= α=βð Þ in the (a) LR, (b) AP, and (c) CC directions. Closed squares,
closed triangles, and cross symbols show the BCFs for α=β = 3, 5,
10 Gy, respectively. AP, anterior‐posterior; CC, cranio‐caudal; LR,
left‐right.
F I G . 13 . The biological conversion factor (BCF) of the (a) D95% and (b) D98% with the d= α=βð Þ. Closed red circles, plus symbols, and cross symbols
are the data of the BCF along the LR, AP, and CC directions. Error bars represent the standard error of the mean. Solid black and green curves are the
results of the fitting using Eq. (10) for the transverse (LR and AP) and longitudinal (CC) data. The AT, BT, and CT are fitting parameters for the transverse
direction, and the AL, BL, and CL are fitting parameters for the longitudinal direction. AP, anterior‐posterior; CC, cranio‐caudal; LR, left‐right.
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for the DPFs examined through the comparison between the BDM
and PDM in this study. The BDM is smaller with larger DPF and
higher α=β. It was affected by the dose gradient. The dose gradi-
ent in physical dose was significantly smaller than that in the BED
at the d= α=βð Þ examined through the comparison. Also, the dose
gradient in the BED is lager with higher d= α=βð Þ. The plan in the
BED with higher d= α=βð Þ is less forgiving of set‐up inaccuracies
owing to steep dose gradients. Therefore, in order to give the
appropriate BDM in the BED‐based treatment planning, the depen-
dency of the BDM on the DPF and α=β should be taken into
account.
This study introduced a new index, the BCF, to convert the
PDM to BDM. Since the BDM and PDM in the CC direction were
larger than the transverse direction, the BCF model was developed
separately for the transverse and longitudinal directions. For the
clinical introduction of the BCF, the flowchart is shown as Fig. 14.
Using the BCF, a direct estimation of the BDM is possible without
calculating the BED. Namely, the BCF provides the opportunities
to give the biologically equivalent DM used in the current PD‐
based treatment planning in the SBRT clinical practice without
built‐in functions of the biological conversion of the dose distribu-
tion. In the clinical process, at first, the PDM is calculated
obtained in commercially treatment planning. After that, the BDM
can be obtained without built‐in functions of the biological conver-
sion of the dose distribution. Additionally, the optimal BDM for
the BED when the dose per fraction is changed can also be
derived.
The simple LQ model is not considered the proliferation and
repair of tumors during the whole course of treatment. However, it
should be noted that the concept of the BCF is not specific for the
LQ model. There were several proposed models for SBRT therapeu-
tic schemes except for LQ model, such as the Linear‐Quadratic‐Lin-
ear (LQL) model, the modified Linear‐Quadratic (MQL) model, the
generalized Linear‐Quadratic (gLQ) model.36–38 The model of the
BCF can be applied to these biological models and various tumor
types through the procedure developed in this study.
The BCF developed in this study can be introduced in the
SBRT clinical practice with the current PD‐based treatment
planning system with no built‐in BED‐related functions. In practice,
the PDM is determined using the SBRT treatment plans for the
commissioning. The BDM is then obtained using the BCF using
Eqs. (9 and 10). This study analyzed 10 treatment plans and the
BCF had variation. Further studies should be needed to reduce the
variation. However, this study provides a new framework to give
the BDM in the current PD‐based treatment planning system. This
novel scheme can be used as a substitute method of the BED‐
based treatment planning in the current PD‐based treatment plan-
ning system.
The limitation of this study was that the BDM of only one com-
bination of the treatment technique and the treatment site was eval-
uated with limited number of patients. The accuracy of the BDM for
lung cancer and the other cancers will be evaluated in the further
study.
5 | CONCLUSION
A novel scheme for the direct estimation of the BDM from the PD
distribution was developed in this study. The setup error was taken
into account for the DM used in this study. The effects of the DPF
and α=β were involved into the BCF which provided the direct con-
version from the PDF to BDM. This scheme is applicable for the var-
ious prescribed doses and fractionations. It is also possible to replace
the BCF by replacing the LQ model by some other biological model.
The BCF model is useful for evaluating the BED coverage to the tar-
get volume, which plays an equivalent role of the BED‐based treat-






F I G . 14 . The flowchart of the clinical
introduction of the biological conversion
factor (BCF).
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